Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab ± Ociperlimab for PD-L1–positive advanced ESCC (2L)
CTR20213241Phase 2Completed
- Sponsor
- BeiGene
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, ociperlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Dec 2021; status: completed.
02
Drugs
tislelizumabociperlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20213241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213241.